{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/BNTX/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-23T07:58:36.380Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":4425,"canonical_name":"BioNTech SE","cik":"0001776985","uei":null,"lei":null,"duns":null,"ticker":"BNTX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":16,"clinical":13,"open":1},"count":30,"timeline":[{"ts":"2026-09-11","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-09-11","url_slug":"/sec/cik-0001776985/4/0002123975-26-000013","accession_number":"0002123975-26-000013","importance":30},{"ts":"2026-09-10","kind":"sec.insider.s","reporter":"Sahin Ugur","title":"Chief Executive Officer","shares":20500,"price_per_share":96.3067,"usd_value":1974287,"security_title":"Ordinary Shares","importance":36.97428735},{"ts":"2026-06-26","kind":"sec.filing","form_type":"3","title":"3 — BioNTech SE — 2026-06-26","url_slug":"/sec/cik-0001776985/3/0001938363-26-000006","accession_number":"0001938363-26-000006","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"3","title":"3 — BioNTech SE — 2026-06-26","url_slug":"/sec/cik-0001776985/3/0002138283-26-000002","accession_number":"0002138283-26-000002","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-06-08","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000041","accession_number":"0001776985-26-000041","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-06-01","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000039","accession_number":"0001776985-26-000039","importance":30},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"BioNTech SE","title":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06827236","excerpt":"[\"Locally Advanced Breast Cancer\",\"Unresectable Breast Carcinoma\",\"Metastatic Breast Cancer\"]","importance":45},{"ts":"2026-05-15","kind":"sec.filing","form_type":"6-K","title":"6-K — BioNTech SE — 2026-05-15","url_slug":"/sec/cik-0001776985/6-k/0001776985-26-000035","accession_number":"0001776985-26-000035","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — BioNTech SE — 2026-05-15","url_slug":"/sec/cik-0001776985/schedule-13g-a/0002123975-26-000006","accession_number":"0002123975-26-000006","importance":30},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"BioNTech SE","title":"A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04486378","excerpt":"[\"Colorectal Cancer Stage II\",\"Colorectal Cancer Stage III\"]","importance":45},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"BioNTech SE","title":"Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07455734","excerpt":"[\"Advanced Solid Tumor Cancer\"]","importance":45},{"ts":"2026-05-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — BioNTech SE — 2026-05-14","url_slug":"/sec/cik-0001776985/schedule-13g-a/0002085929-26-000009","accession_number":"0002085929-26-000009","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-05-13","url_slug":"/sec/cik-0001776985/4/0001955589-26-000004","accession_number":"0001955589-26-000004","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-05-13","url_slug":"/sec/cik-0001776985/4/0002118987-26-000002","accession_number":"0002118987-26-000002","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-05-13","url_slug":"/sec/cik-0001776985/4/0002123964-26-000006","accession_number":"0002123964-26-000006","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-05-13","url_slug":"/sec/cik-0001776985/4/0002123971-26-000004","accession_number":"0002123971-26-000004","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"4","title":"4 — BioNTech SE — 2026-05-13","url_slug":"/sec/cik-0001776985/4/0002123980-26-000005","accession_number":"0002123980-26-000005","importance":30},{"ts":"2026-05-12","kind":"sec.form144","reporter":"Medine GmbH","title":"Officer, 10% Stockholder","shares":858209,"usd_value":80379855,"security_title":"American Depositary Shares representing ordinary shares, no par value per share","approx_sale_date":"2026-05-13","accession_number":"0002056296-26-000003","importance":56.075970987999995},{"ts":"2026-05-12","kind":"sec.filing","form_type":"144","title":"144 — BioNTech SE — 2026-05-12","url_slug":"/sec/cik-0001776985/144/0002056296-26-000003","accession_number":"0002056296-26-000003","importance":30},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"BioNTech SE","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07173751","excerpt":"[\"Breast Neoplasms\"]","importance":60},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"BioNTech SE","title":"A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07255404","excerpt":"[\"Pancreatic Ductal Adenocarcinoma (PDAC)\"]","importance":45},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"BioNTech SE","title":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06841055","excerpt":"[\"Non-small Cell Lung Cancer\"]","importance":45},{"ts":"2026-04-17","kind":"clinical.trial","reporter":"BioNTech SE","title":"A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07079631","excerpt":"[\"Metastatic Colorectal Cancer\"]","importance":45},{"ts":"2026-04-15","kind":"clinical.trial","reporter":"BioNTech SE","title":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","security_title":"PHASE2,PHASE3","status":"RECRUITING","accession_number":"NCT06712316","excerpt":"[\"Non-small Cell Lung Cancer\"]","importance":60},{"ts":"2026-04-15","kind":"clinical.trial","reporter":"BioNTech SE","title":"A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria","security_title":"PHASE1,PHASE2","status":"COMPLETED","accession_number":"NCT06069544","excerpt":"[\"Malaria\"]","importance":45},{"ts":"2026-04-15","kind":"clinical.trial","reporter":"BioNTech SE","title":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06892548","excerpt":"[\"Advanced Lung Cancer\"]","importance":45},{"ts":"2026-04-14","kind":"clinical.trial","reporter":"BioNTech SE","title":"Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT05142189","excerpt":"[\"Non-Small Cell Lung Cancer\"]","importance":30},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"BioNTech SE","title":"A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07300839","excerpt":"[\"COVID-19\",\"SARS-COV-2 Infection\"]","importance":60},{"ts":"2026-04-06","kind":"clinical.trial","reporter":"BioNTech SE","title":"A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07147348","excerpt":"[\"Advanced Solid Tumor\"]","importance":45},{"ts":"2024-12-31","kind":"open.payments","reporter":"BioNTech SE","title":"$213387.0 to 45 physicians (2024–2024)","security_title":"manufacturer","excerpt":"COMIRNATY","accession_number":"2024","usd_value":213387,"importance":70}]}